The contraceptive vaginal ring

Document Type

Journal Article

Publication Date

4-13-2010

Journal

Seminars in Reproductive Medicine

Volume

28

Issue

2

DOI

10.1055/s-0030-1248138

Keywords

NuvaRing; Vaginal contraception; Vaginal ring

Abstract

The contraceptive vaginal ring offers effective contraception that is self-administered, requires less frequent dosing than many other forms of contraception, and provides low doses of hormones. NuvaRing (Organon, Oss, The Netherlands), the only contraceptive vaginal ring approved for use in the United States, contains etonogestrel and ethinyl estradiol. It is inserted into the vagina for 3 weeks, followed by a 1-week ring-free period, and works by inhibiting ovulation. Most women note a beneficial effect on bleeding profiles and are satisfied with NuvaRing. Commonly reported adverse events include vaginitis, leukorrhea, headaches, and device-related events such as discomfort. Serious adverse events are rare. In Chile and Peru, progesterone-only vaginal contraceptive rings are available for nursing women. Studies are ongoing examining new formulations of vaginal contraceptive rings. © 2010 by Thieme Medical Publishers, Inc.

Link to Full Text

Share

COinS